We are proud to announce that PhenoPath is now part of AmeriPath.
PhenoPath, PLLC
Diagnoses you can count on®
PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:
- PhenoPath's cobas® EGFR Plasma Mutation Test (IVD)
- Plasma cfDNA EGFR Mutation Testing Requisition Form
Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.
Latest News
-
PhenoPath acquired by Quest Diagnostics
Please read the attached letter for an important announcement regarding PhenoPath
Read More » -
Phenomena v21.1
New FDA Approvals for PD-L1/PD-1 Targeted Therapies & Introducing the Combined Positive Score (CPS); New Assays MUC4 IHC and TFE3 (Xp11) FISH; Amyloid Analysis;...
Read More » -
Phenomena v20.2 (Fall 2017)
PhenoPath newsletter featuring the latest on RAS gene testing, "double-hit" B cell lymphomas, and a new marker for small cell carcinoma of the ovary.... Read More »